<link rel="stylesheet" href="http://raw.githubusercontent.com/sindresorhus/github-markdown-css/gh-pages/github-markdown.css">
<style>
    .markdown-body {
        min-width: 200px;
        max-width: 790px;
        margin: 0 auto;
        padding: 30px;
    }
</style>
<article class="markdown-body">

<h1>Turmeric and its effects on breast cancer</h1>

Summary generated using:
<code>$shovel3 query.concatConclusions &#x27;breast cancer turmeric site:ncbi.nlm.nih.gov&#x27; 40 includeReference=True</code>

<ul>

      <li>
        Based on the results, curcumin inhibits the expression and secretion of leptin and it could probably be used as a drug candidate for the breast cancer therapy through the leptin targeting in the future.
        <ul>
          <li>Journal: </li>
          <li>Date: </li>
          <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392783/">Link to article</a></li>
        </ul
      </li>

      <li>
        The SK-BR-3 cells and DMBA-induced tumors, both with an ER- and Her-2+ phenotype, were affected by the synergistic interaction of DHA and CCM. This suggests that the specific breast cancer phenotype is an important factor for predicting efficacy of these nutraceuticals. The combination of DHA and CCM is potentially a dietary supplemental treatment for some breast cancers, likely dependent upon the molecular phenotype of the cancer.
        <ul>
          <li>Journal: </li>
          <li>Date: </li>
          <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24034496/">Link to article</a></li>
        </ul
      </li>

      <li>
        Rosemary/carnosic acid, alone or combined with curcumin, may be useful to prevent and treat ER-negative breast cancer. Copyright © 2012 Elsevier B.V. All rights reserved.
        <ul>
          <li>Journal: Fitoterapia</li>
          <li>Date: 04/28/15</li>
          <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/22828666">Link to article</a></li>
        </ul
      </li>

      <li>
        Curcumin suppresses the expression level of FABP5 and PPARβ/δ in triple negative mammary carcinoma cells. By targeting the FABP5/PPARβ/δ pathway, curcumin prevents the delivery of retinoic acid to PPARβ/δ and suppresses retinoic acid-induced PPARβ/δ target gene, VEGF-A. Our data demonstrates that suppression of the FABP5/ PPARβ/δ pathway by curcumin sensitizes retinoic acid resistant triple negative breast cancer cells to retinoic acid mediated growth suppression.
        <ul>
          <li>Journal: </li>
          <li>Date: </li>
          <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192446/">Link to article</a></li>
        </ul
      </li>

</ul>

</article>
